On March 1, 2019 MaxCyte, the global cell-based medicines and life sciences company, reported that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement (Press release, MaxCyte, MAR 1, 2019, View Source [SID1234537626]). Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re excited to take our relationship with Kite further into product development, providing the company the ability to leverage MaxCyte’s versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics," said Doug Doerfler, President & CEO of MaxCyte, Inc.

The expansion of the Kite-MaxCyte relationship builds on an existing research agreement announced in November 2018. Under the terms of the new license agreement, Kite obtains non-exclusive clinical and commercial-use rights to MaxCyte’s cell engineering platform to develop CAR-T therapies, and MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.